

CYP27B1 Antibody (C-term) Blocking peptide

Synthetic peptide Catalog # BP12284b

Specification

CYP27B1 Antibody (C-term) Blocking peptide -Product Information

Primary Accession 015528

CYP27B1 Antibody (C-term) Blocking peptide -Additional Information

Gene ID 1594

Other Names

25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, 25-OHD-1 alpha-hydroxylase, 25-hydroxyvitamin D(3) 1-alpha-hydroxylase, VD3 1A hydroxylase, Calcidiol 1-monooxygenase, Cytochrome P450 subfamily XXVIIB polypeptide 1, Cytochrome P450C1 alpha, Cytochrome P450VD1-alpha, Cytochrome p450 27B1, CYP27B1, CYP1ALPHA, CYP27B

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CYP27B1 Antibody (C-term) Blocking peptide -Protein Information

Name CYP27B1

Synonyms CYP1ALPHA, CYP27B

Function A cytochrome P450 monooxygenase

CYP27B1 Antibody (C-term) Blocking peptide - Background

This gene encodes a member of the cytochrome P450superfamily of enzymes. The cytochrome P450 proteins aremonooxygenases which catalyze many reactions involved in drugmetabolism and synthesis of cholesterol, steroids and other lipids.The protein encoded by this gene localizes to the innermitochondrial membrane where it hydroxylates 25-hydroxyvitamin D3at the 1alpha position. This reaction synthesizes1alpha,25-dihydroxyvitamin D3, the active form of vitamin D3, whichbinds to the vitamin D receptor and regulates calcium metabolism. Thus this enzyme regulates the level of biologically active vitaminD and plays an important role in calcium homeostasis. Mutations inthis gene can result in vitamin D-dependent rickets type I.

CYP27B1 Antibody (C-term) Blocking peptide - References

Giroux, S., et al. Bone 47(5):975-981(2010)Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Holt, S.K., et al. Prostate 70(13):1448-1460(2010)Alzahrani, A.S., et al. J. Clin. Endocrinol. Metab. 95(9):4176-4183(2010)Sundqvist, E., et al. Eur. J. Hum. Genet. (2010) In press :



involved in vitamin D metabolism and in calcium and phosphorus homeostasis. Catalyzes the rate-limiting step in the activation of vitamin D in the kidney, namely the hydroxylation of 25-hydroxyvitamin D3/calcidiol at the Clalpha- position to form the hormonally active form of vitamin D3, 1alpha,25dihydroxyvitamin D3/calcitriol that acts via the vitamin D receptor (VDR) (PubMed: <a h ref="http://www.uniprot.org/citations/10518 789" target=" blank">10518789, PubMed:9486994, PubMed:22862690, PubMed:10566658, PubMed:12050193). Has 1alpha-hydroxylase activity on vitamin D intermediates of the CYP24A1-mediated inactivation pathway (PubMed:10518789, PubMed: 22862690). Converts 24R,25-dihydroxyvitamin D3/secalciferol to 1-alpha,24,25-trihydroxyvitamin D3, an active ligand of VDR. Also active on 25-hvdroxvvitamin D2 (PubMed:10518789). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via FDXR/adrenodoxin reductase and FDX1/adrenodoxin (PubMed:22862690).

Cellular Location Mitochondrion membrane.

Tissue Location Kidney.

CYP27B1 Antibody (C-term) Blocking peptide - Protocols



Provided below are standard protocols that you may find useful for product applications.

Blocking Peptides